Current and emerging therapies for the treatment of myasthenia gravis

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 151-160

  Mantegazza, Renato ^a   Bonanno, Silvia ^a   Camera, Giorgia ^a   Antozzi, Carlo ^a  

^a Fondazione Istituto Neurologico   (Italy)

Author keywords

Immunosuppression; Myasthenia gravis; Plasmapheresis; Therapy; Thymectomy

Indexed keywords

ACETYLCHOLINESTERASE; ANTISENSE OLIGONUCLEOTIDE; ATROPINE; AUTOANTIBODY; AZATHIOPRINE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; CHOLINESTERASE INHIBITOR; COMPLEMENT INHIBITOR; COMPLEMENTARY RNA; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; EN 101; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOSTIGMINE; NEOSTIGMINE METHYL SULFATE; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ASTHMA; BEDTIME DOSAGE; BLURRED VISION; BONE MARROW TOXICITY; BRONCHUS SECRETION; CATARACT; CELL THERAPY; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EYE DISEASE; FASCICULATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL IRRITATION; GLAUCOMA; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; IMMUNOADSORPTION; IMMUNOMODULATION; INTESTINAL DYSMOTILITY; LIVER TOXICITY; LOW DRUG DOSE; MINIMALLY INVASIVE SURGERY; MUSCLE CRAMP; MYASTHENIA GRAVIS; NEPHROTOXICITY; NEUROMUSCULAR SYNAPSE; NEUROMUSCULAR TRANSMISSION; NONHUMAN; OSTEOPOROSIS; PLASMAPHERESIS; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; SURGICAL APPROACH; SWEATING; THYMECTOMY; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 80053634167     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S8915     Document Type: Review

References (84)

1. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26(11): 1054-1059.
2. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 2002;2(10):797-804.
3. Souroujon MC, Brenner T, Fuchs S. Development of novel therapies for MG: Studies in animal models. Autoimmunity. 2010;43(5-6): 446-460.
4. Wolfe GI, Oh SJ. Clinical phenotype of muscle-specific tyrosine kinaseantibody- positive myasthenia gravis. Ann N Y Acad Sci. 2008;1132: 71-75.
5. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain. 2008;131(7): 1940-1952.
6. Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol. 2005;57(2):289-293.
7. Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology. 2004;62(11): 1945-1950.
8. Cole RN, Reddel SW, Gervásio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol. 2008;63(6):782-789.
9. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330(25): 1797-1810.
10. Bernasconi P, Barberis M, Baggi F, et al. Increased Toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol. 2005;167(1):129-139.
11. Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol. 2010; 67(6):726-738.
12. Evoli A, Minisci C, Di Schino C, et al. Thymoma in patients with MG: characteristics and long-term outcome. Neurology. 2002;59(12): 1844-1850.
13. Maggi L, Andreetta F, Antozzi C, et al. Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 patients on a 20-year experience. J Neuroimmunol. 2008;201-202:237-244.
14. Phillips LH 2nd, Torner JC. Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology. 1996;47(5):1233-1238.
15. Phillips LH 2nd. The epidemiology of myasthenia gravis. Ann N Y Acad Sci. 2003;998:407-412.
16. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009;8(5): 475-490.
17. Aragonès JM, Bolíbar I, Bonfill X, et al. Myasthenia gravis: a higher than expected incidence in the elderly. Neurology. 2003;60(6):1024-1026.
18. Vincent A, Clover L, Buckley C, et al. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry. 2003;74(8):1105-1108.
19. Aarli JA. Myasthenia gravis in the elderly: Is it different? Ann N Y Acad Sci. 2008;1132:238-243.
20. Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J Neurol. 1988;235(8):449-453.
21. Jaretzki A 3rd, Barhon RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000;55(1):16-23.
22. Benathar M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007;68(24):2144-2149.
23. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2006;13(7):691-699.
24. Sieb JP, Köhler W. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial. Clin Neurol Neurosurg. 2010;112(9):781-784.
25. Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med. 1997;25(7):1228-1235.
26. Mayer SA, Thomas CE. Therapy of myasthenic crisis. Crit Care Med. 1998;26(6):1136-1137.
27. Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989;52(10):1121-1127.
28. Osserman KE. Progress report on mestinon bromide (pyridostigmine bromide). Am J Med. 1955;19(5):737-739.
29. Meda Group, Sweden. (Data on file).
30. Beekman R, Kuks JB, Oosterhuis HJ. Myasthenia gravis: diagnosis and follow-up of 100 consecutive patients. J Neurol. 1997;244(2):112-118.
31. Punga AR, Sawada M, Stålberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve. 2008;37(3):300-307.
32. Shapira M, Tur-Kaspa I, Bosgraaf L, et al. A transcription-activating polymorphism in the ACHE promoter associated with acute sensitivity to anti-acetylcholinesterases. Hum Mol Genet. 2000;9(9):1273-128.
33. Ahmed S, Kirmani JF, Janjua N, et al. An update on myasthenic crisis. Curr Treat Options Neurol. 2005;7(2):129-141.
34. Lacomis D. Myasthenic crisis. Neurocrit Care. 2005;3(3):189-194.
35. Jani-Acsadi A, Lisak RP. Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci. 2007;261(1-2):127-133.
36. Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci. 2008;1132:76-83.
37. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126(10):2304-2311.
38. Punga AR, Flink R, Askmark H, Stålberg EV. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody. Muscle Nerve. 2006;34(1):111-115.
39. Ferrero S, Pretta S, Nicoletti A, Petrera P, Ragni N. Myasthenia gravis: management issues during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2005;121(2):129-138.
40. Hoff JM, Daltveit AK, Gilhus NE. Myasthenia gravis in pregnancy and birth: identifying risk factors, optimising care. Eur J Neurol. 2007;14(1): 38-43.
41. Fauci AS, Dale DC, Balow JE. Glucocorticosteroid therapy: mechanism of action and clinical consideration. Ann Intern Med. 1976;84(3): 304-315.
42. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984;15(3): 291-298.
43. Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology. 1984;34(2):170-174.
44. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR. Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev. 2005;(2): CD002828.
45. Kupersmith MJ. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol. 2009;256(8): 1314-1320.
46. Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23(4):251-255.
47. Hart IK, Sathasivam S, Sharshar T. Immunosuppressive agents for myasthenia gravis. Cochrane Database Syst Rev. 2007;(4): CD005224.
48. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50(6): 1778-1783.
49. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 2003;348(6):538-549.
50. Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987;316(12):719-724.
51. Drachman DB, Adams RN, Hu R, Johns RJ, Brodsky RA. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci. 2008;1132:305-314.
52. Sanders DB, Hart IK, Mantegazza R, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology. 2008;71(6):400-406.
53. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology. 2008;71(6):394-399.
54. Antozzi C, Gemma M, Regi B, et al. A short plasma exchange protocol is effective in severe myasthenia gravis. J Neurol. 1991;238(2): 103-107.
55. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002;(4):CD002275.
56. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin. Arch Neurol. 2005;62(11):1689-1693.
57. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis. A randomized controlled trial. Neurology. 2007;68(11): 837-841.
58. Gajdos P, Chevret S, et al. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2008;(1):CD002277.
59. Donofrio PD, Berger A, Brannagan TH 3rd, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. Muscle Nerve. 2009;40(5):890-900.
60. Samuelsson G. Extracorporeal immunoadsorption with protein A: technical aspects and clinical results. J Clin Apher. 2001;16(1):49-52.
61. Bosch T. Therapeutic apheresis. State of the art in the year 2005. Ther Apher Dial. 2005;9(6):459-468.
62. Buckingham JM, Howard FM Jr, Bernatz PE, et al. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg. 1976;184:453-458.
63. Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55(1):7-15.
64. Mantegazza R, Baggi F, Bernasconi P, et al. Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. J Neurol Sci. 2003;212(1-2):31-36.
65. Gilbert ME, de Sousa EA, Savino PJ. Ocular myasthenia gravis treatment: the case against prednisone therapy and thymectomy. Arch Neurol. 2007;64(12):1790-1792.
66. Luchanok U, Kaminski HJ. Ocular myasthenia: diagnostic and treatment recommendations and the evidence base. Curr Opin Neurol. 2008;21(1): 8-15.
67. Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol. 2008;201-202:90-94.
68. Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol. 2009;16(2):246-250.
69. Nelson RP Jr, Pascuzzi RM, Kessler K, et al. Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review. J Clin Neuromuscul Dis. 2009;10(4):170-177.
70. Stieglbauer K, Topakian R, Schäffer V, Aichner FT. Rituximab for myasthenia gravis: three case reports and review of the literature. J Neurol Sci. 2009;280(1-2):120-122.
71. Christadoss P, Goluszko E. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. J Neuroimmunol. 2002;122(1-2):186-190.
72. Rowin J, Meriggioli MN, Tuzun E, Leurgans S, Christadoss P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004;63(12):2390-2392.
73. Tuzun E, Meriggioli MN, Rowin J, Yang H, Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun. 2005;24(3):261-268.
74. Christadoss P, Tuzun E, Li J, Saini SS, Yang H. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann N Y Acad Sci. 2008;1132:210-219.
75. Baggi F, Andreetta F, Caspani E, et al. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. J Clin Invest. 1999;104(9): 1287-1295.
76. Im SH, Barchan D, Fuchs S, Souroujon MC. Mechanism of nasal tolerance induced by a recombinant fragment of acetylcholine receptor for treatment of experimental myasthenia gravis. J Neuroimmunol. 2000;111(1-2):161-168.
77. Argov Z, McKee D, Agus S, et al. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology. 2007;69(7):699-700.
78. Sussman JD, Argov Z, McKee D, Hazum E, Brawer S, Soreq H. Antisense treatment for myasthenia gravis: experience with monarsen. Ann N Y Acad Sci. 2008;1132:283-290.
79. Xiao BG, Duan RS, Link H, Huang YM. Induction of peripheral tolerance to experimental autoimmune myasthenia gravis by acetylcholine receptor-pulsed dendritic cells. Cell Immunol. 2003;223(1):63-69.
80. Duan RS, Adikari SB, Huang YM, Link H, Xiao BG. Protective potential of experimental autoimmune myasthenia gravis in Lewis rats by IL-10-modified dendritic cells. Neurobiol Dis. 2004;16(2):461-467.
81. Sheng JR, Li LC, Ganesh BB, Prabhakar BS, Meriggioli MN. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol. 2008;128(2):172-180.
82. Tzartos S, Bitzopoulou K, Gavra I, et al. Antigen-specific apheresis of pathogenic autoantibodies from myasthenia gravis sera. Ann N Y Acad Sci. 2008;1132:291-299.
83. Losen M, Martinez-Martinez P, Phernambucq M, et al. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation. Ann N Y Acad Sci. 2008;1132:174-179.
84. Schuurman J, Losen M, et al. Anti- inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317(5844):1554-1557.